A Clinical Study of MK-4208/TERN-701 in Participants With Chronic Myeloid Leukemia (CML) (MK-4208-003/Tern701-1012/CARDINAL)

Inclusion Criteria

• Key Inclusion Criteria: Inclusion Criteria include but are not limited to: - Have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2 - Have an established cytopathologically confirmed diagnosis of breakpoint cluster region::Abelson (BCR-ABL1) positive Chronic Myeloid Leukemia (CML) in Chronic Phase - Have received treatment with at least one prior tyrosine kinase inhibitor (TKI) and have treatment failure, suboptimal response, or treatment intolerance - Prior treatment with asciminib is allowed - Adequate organ function, as assessed by local laboratory Key Exclusion Criteria: Exclusion criteria include but are not limited to: - Systemic antineoplastic therapy (including prior TKIs, interferon-alfa, therapeutic antibodies, chemotherapy) or other experimental therapy 7 days before the first dose of MK-4208/TERN-701 - Have completed previous anticancer therapy without resolution of all associated clinically significant toxicity (to ≤ Grade 2 or baseline)